[{"address1": "3027 Townsgate Road", "address2": "Suite 300", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 418 5006", "website": "https://www.arcutis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 342, "companyOfficers": [{"maxAge": 1, "name": "Mr. Todd Franklin Watanabe M.A.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 1230634, "exercisedValue": 0, "unexercisedValue": 4432512}, {"maxAge": 1, "name": "Dr. Bhaskar  Chaudhuri Ph.D.", "age": 70, "title": "Co-Founder & Director Emeritus", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 65000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masaru  Matsuda Esq., J.D.", "age": 54, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 749940, "exercisedValue": 0, "unexercisedValue": 415027}, {"maxAge": 1, "name": "Dr. Patrick E. Burnett M.D., Ph.D.", "age": 53, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 814766, "exercisedValue": 344719, "unexercisedValue": 59168}, {"maxAge": 1, "name": "Mr. Larry Todd Edwards", "age": 62, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 833908, "exercisedValue": 0, "unexercisedValue": 999527}, {"maxAge": 1, "name": "Ms. Latha  Vairavan", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rajvir  Madan", "title": "Chief Digital & Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Schoelkopf", "title": "Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Arias", "title": "Vice President of Compliance & Privacy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amanda  Sheldon", "title": "Head of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 26.07, "open": 26.5, "dayLow": 26.405, "dayHigh": 27.5, "regularMarketPreviousClose": 26.07, "regularMarketOpen": 26.5, "regularMarketDayLow": 26.405, "regularMarketDayHigh": 27.5, "payoutRatio": 0.0, "beta": 1.683, "forwardPE": 59.762875, "volume": 1257231, "regularMarketVolume": 1257231, "averageVolume": 1942555, "averageVolume10days": 1237640, "averageDailyVolume10Day": 1237640, "bid": 19.62, "ask": 34.17, "bidSize": 2, "askSize": 2, "marketCap": 3346486528, "fiftyTwoWeekLow": 11.13, "fiftyTwoWeekHigh": 31.77, "allTimeHigh": 40.88, "allTimeLow": 1.76, "priceToSalesTrailing12Months": 10.525893, "fiftyDayAverage": 28.3118, "twoHundredDayAverage": 19.83485, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3269192704, "profitMargins": -0.13941, "floatShares": 89448698, "sharesOutstanding": 122492192, "sharesShort": 15221587, "sharesShortPriorMonth": 13235954, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.1243, "heldPercentInsiders": 0.01671, "heldPercentInstitutions": 1.04198, "shortRatio": 8.01, "shortPercentOfFloat": 0.1527, "impliedSharesOutstanding": 122492192, "bookValue": 1.314, "priceToBook": 20.791475, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -44324000, "trailingEps": -0.34, "forwardEps": 0.45714, "enterpriseToRevenue": 10.283, "enterpriseToEbitda": -98.502, "52WeekChange": 1.2493529, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 27.32, "targetHighPrice": 37.0, "targetLowPrice": 29.0, "targetMeanPrice": 31.75, "targetMedianPrice": 31.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 191068000, "totalCashPerShare": 1.56, "ebitda": -33189000, "totalDebt": 113774000, "quickRatio": 3.069, "currentRatio": 3.5, "totalRevenue": 317928992, "debtToEquity": 71.976, "revenuePerShare": 2.515, "returnOnAssets": -0.05914, "returnOnEquity": -0.28168, "grossProfits": 286016992, "freeCashflow": -42323376, "operatingCashflow": -32558000, "revenueGrowth": 1.217, "grossMargins": 0.89962995, "ebitdaMargins": -0.10439, "operatingMargins": 0.085930005, "financialCurrency": "USD", "symbol": "ARQT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Arcutis Biotherapeutics, Inc.", "longName": "Arcutis Biotherapeutics, Inc.", "earningsTimestamp": 1772053200, "earningsTimestampStart": 1772053200, "earningsTimestampEnd": 1772053200, "earningsCallTimestampStart": 1772055000, "earningsCallTimestampEnd": 1772055000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.34, "epsForward": 0.45714, "epsCurrentYear": -0.13714, "priceEpsCurrentYear": -199.21248, "fiftyDayAverageChange": -0.9918003, "fiftyDayAverageChangePercent": -0.03503134, "twoHundredDayAverageChange": 7.4851494, "twoHundredDayAverageChangePercent": 0.37737364, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1770423644, "regularMarketTime": 1770411602, "exchange": "NMS", "messageBoardId": "finmb_549019944", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.79478, "regularMarketPrice": 27.32, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1580481000000, "postMarketChangePercent": -0.07357116, "postMarketPrice": 27.2999, "postMarketChange": -0.02009964, "regularMarketChange": 1.25, "regularMarketDayRange": "26.405 - 27.5", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1942555, "fiftyTwoWeekLowChange": 16.189999, "fiftyTwoWeekLowChangePercent": 1.454627, "fiftyTwoWeekRange": "11.13 - 31.77", "fiftyTwoWeekHighChange": -4.450001, "fiftyTwoWeekHighChangePercent": -0.14006928, "fiftyTwoWeekChangePercent": 124.935295, "displayName": "Arcutis Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]